论文部分内容阅读
目的探讨并研究联合应用美多巴与普拉克索治疗帕金森病的临床疗效,从而提高临床上对帕金森病患者的治疗效果。方法抽取2013年9月至2015年9月收治的帕金森病患者120例作为研究对象,依据电脑所产生的随机数列将120例患者分为两组,对照组患者仅服用美多巴进行治疗,研究组患者同时服用美多巴和普拉克索进行治疗,治疗时间为12周。对两组患者的临床疗效进行对比,并观察两组患者治疗前和治疗后4周、8周、12周汉密尔顿抑郁量表(HAMD)评分和帕金森评分量表Ⅲ(UPDRSⅢ)评分的变化以及不良反应的发生情况。结果两组患治疗后HAMD评分和UPDRSⅢ评分与治疗前相比均明显降低,研究组患者在治疗后4、8、12周的UPDRSⅢ评分及HAMD评分与对照组相比明显降低(P<0.05,P<0.01)。研究组的治疗总有效率(91.67%)明显高于对照组的治疗总有效率(68.33%),差异有统计学意义(P均<0.01)。两组患者在治疗过程中均出现嗜睡、失眠、恶心呕吐、开关现象、精神症状、头晕等不良反应,研究组患者不良反应的发生率为23.33%,对照组患者不良反应的发生率为46.67%,差异有统计学意义(P<0.01)。结论联合应用美多巴与普拉克索治疗帕金森病能有效缓解患者的临床症状,改善生活质量,提高临床治疗效果,且具有较高的安全性。
Objective To investigate and study the clinical efficacy of combined use of metopar and pramipexole in the treatment of Parkinson’s disease so as to improve the clinical effect of treatment on Parkinson’s disease patients. Methods Totally 120 patients with Parkinson’s disease who were admitted to our hospital from September 2013 to September 2015 were selected as the research object. 120 patients were divided into two groups according to the random number sequence generated by the computer. Patients in the control group were treated with only metoprolol, Patients in the study group were treated with both metoparavir and pramipexole for a mean of 12 weeks. The clinical efficacy of the two groups were compared and the change of Hamilton Depression Rating Scale (HAMD) and Parkinson’s Rating Scale Ⅲ (UPDRS Ⅲ) scores before and after 4 weeks, 8 weeks and 12 weeks after treatment were compared between the two groups Adverse reactions occurred. Results The scores of HAMD and UPDRS Ⅲ in both groups were significantly lower than those before treatment. The UPDRS Ⅲ and HAMD scores in study group at 4, 8 and 12 weeks after treatment were significantly lower than those in control group (P <0.05, P <0.01). The total effective rate of the study group (91.67%) was significantly higher than that of the control group (68.33%), the difference was statistically significant (all P <0.01). Two groups of patients in the course of treatment were drowsiness, insomnia, nausea and vomiting, switching phenomenon, mental symptoms, dizziness and other adverse reactions, the incidence of adverse reactions in the study group was 23.33%, the incidence of adverse reactions in the control group was 46.67% , The difference was statistically significant (P <0.01). Conclusions The combined application of Madopar and pramipexole in the treatment of Parkinson’s disease can effectively alleviate the clinical symptoms of patients, improve the quality of life, and improve the clinical effect, and has high safety.